Physician profile
Robert M Bayless
NPI 1306555826
$6,170.78
in general payments reported to CMS, 2019-2025
36 companies · $2,538 in 2025
The $2,538 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,113 · 2024: $1,519 · 2025: $2,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,170.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.08 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $729.71 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $571.77 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Exact Sciences Corporation | $412.06 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $283.34 | 2023-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $278.39 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $277.04 | 2023-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.15 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Novo Nordisk INC | $273.08 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.99 | 2023-2025 | Jardiance, Ofev, Spiriva Respimat |
| Pfizer INC. | $220.44 | 2023-2025 | |
| Lilly USA, LLC | $214.72 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $180.19 | 2023-2025 | Invega Sustenna, Xarelto, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.17 | 2024-2025 | Caplyta |
| Corcept Therapeutics | $106.73 | 2023-2024 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $98.92 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $94.24 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $80.15 | 2025 | Trintellix |
| Astellas Pharma US INC | $79.27 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $78.74 | 2023-2025 | |
| Medtronic, INC. | $77.32 | 2025 | Minimed 780g, Prestige LP Cervical Disc System |
| Vanda Pharmaceuticals INC. | $71.82 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $71.13 | 2023-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $45.01 | 2023 | Vaxelis, Gardasil 9, Rotateq |
| Sumitomo Pharma America, INC. | $34.72 | 2024-2025 | Gemtesa |
| Nevro Corp. | $34.17 | 2024 | Senza |
| Viiv Healthcare Company | $33.77 | 2024 | Apretude |
| Phathom Pharmaceuticals, INC. | $28.60 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $27.11 | 2023 | Crysvita |
| Grifols USA, LLC | $19.95 | 2024 | Prolastin-C Liquid |
| Hologic Sales and Service, LLC | $19.74 | 2023 | Aptima, Thinprep 2000 Processor |
| Edwards Lifesciences Corporation | $19.02 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Recordati_rare_diseases_inc. | $17.10 | 2025 | Isturisa |
| Axsome Therapeutics, INC. | $15.30 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.14 | 2024 | Rexulti |
| Genzyme Corporation | $12.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bayless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.